The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...

Oncopathology or cancer pathology is a specialised branch of pathology focused on diagnosing and characterising tumours ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best high short interest stocks with huge upside potential. On July 2, Jazz ...

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach their full potential and ensure no eligible patient is overlooked.

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission for Ziihera for biliary tract cancer.

This paper is focused on analyzing the potential of RPMA in assessing the expression/activation status of HER family signaling along with downstream signaling effectors in IHC/FISH/HER2 + and IHC ...

Results HER2 IHC 3+ staining was observed in 15 (4.7%) of the 320 tumor samples analyzed and HER2 IHC 2+ in 26 (8.1%; Table 1 ). Low HER2 expression (IHC 0 or 1+) was detected in the 279 (87.2% ...

US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.